View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 22, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	DVAX
Entity Registrant Name	DYNAVAX TECHNOLOGIES CORP
Entity Central Index Key	0001029142
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		63,996,911
Entity Public Float			$ 760,000,000

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 49,348	$ 26,584
Marketable securities available-for-sale	96,188	165,270
Accounts and other receivables, net	3,704	854
Inventories, net	19,022	312
Intangible assets, net		1,306
Prepaid expenses and other current assets	6,102	3,697
Total current assets	174,364	198,023
Property and equipment, net	17,064	16,619
Intangible assets, net	11,717
Goodwill	2,144	2,244
Restricted cash	619	629
Other assets	4,976	1,270
Total assets	210,884	218,785
Current liabilities:
Accounts payable	5,278	4,539
Accrued research and development	9,714	4,359
Accrued liabilities	16,041	9,695
Other current liabilities	7,000
Total current liabilities	38,033	18,593
Long term debt, net	100,871
Other long-term liabilities	8,915	643
Total liabilities	147,819	19,236
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000 shares authorized at December 31, 2018 and December 31, 2017; no shares issued and outstanding at December 31, 2018 and December 31, 2017
Common stock: $0.001 par value; 139,000 shares authorized at December 31, 2018 and 2017; 62,862 and 61,533 shares issued and outstanding at December 31, 2018 and 2017, respectively	63	62
Additional paid-in capital	1,131,241	1,107,693
Accumulated other comprehensive loss	(2,015)	(881)
Accumulated deficit	(1,066,224)	(907,325)
Total stockholders’ equity	63,065	199,549
Total liabilities and stockholders’ equity	$ 210,884	$ 218,785

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	139,000,000	139,000,000
Common stock, shares issued	62,862,000	61,533,000
Common stock, shares outstanding	62,862,478	61,533,000

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 8,198	$ 327	$ 11,043
Operating expenses:
Cost of sales - amortization of intangible assets	10,862	1,194
Research and development	74,951	64,988	84,493
Selling, general and administrative	64,770	27,367	37,257
Restructuring		2,783
Total operating expenses	161,517	96,332	121,750
Loss from operations	(153,319)	(96,005)	(110,707)
Other income (expense):
Interest income	3,828	1,337	755
Interest expense	(9,338)
Other expense, net	(70)	(486)	(2,492)
Net loss	$ (158,899)	$ (95,154)	$ (112,444)
Basic and diluted net loss per share	$ (2.55)	$ (1.81)	$ (2.92)
Weighted average shares used to compute basic and diluted net loss per share	62,362	52,613	38,506
Product
Revenues:
Total revenues	$ 6,812
Operating expenses:
Cost of sales - product	10,934
Cost of sales - amortization of intangible assets	10,862	$ 1,194
Collaboration Revenue
Revenues:
Total revenues	$ 1,386		$ 9,778
Grant Revenue
Revenues:
Total revenues		295	381
Service and License Revenue
Revenues:
Total revenues		$ 32	$ 884

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (158,899)	$ (95,154)	$ (112,444)
Other comprehensive (loss) income, net of tax:
Unrealized gain (loss) on marketable securities available-for-sale	12	(83)	(8)
Cumulative foreign currency translation adjustments	(1,146)	2,826	(686)
Total other comprehensive (loss) income	(1,134)	2,743	(694)
Total comprehensive loss	$ (160,033)	$ (92,411)	$ (113,138)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning Balances at Dec. 31, 2015	$ 187,079	$ 38	$ 889,698	$ (2,930)	$ (699,727)
Beginning Balances (in shares) at Dec. 31, 2015		38,446
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net	(83)	$ 1	(84)
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)		107
Issuance of common stock under Employee Stock Purchase Plan	615		615
Issuance of common stock under Employee Stock Purchase Plan (in shares)		46
Stock compensation expense	14,728		14,728
Total other comprehensive loss	(694)			(694)
Net loss	(112,444)				(112,444)
Ending Balances at Dec. 31, 2016	89,201	$ 39	904,957	(3,624)	(812,171)
Ending Balances (in shares) at Dec. 31, 2016		38,599
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net	1,613		1,613
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)		262
Issuance of common stock under Employee Stock Purchase Plan	293		293
Issuance of common stock under Employee Stock Purchase Plan (in shares)		84
Issuance of common stock, net of issuance costs	185,936	$ 23	185,913
Issuance of common stock, net of issuance costs (in shares)		22,588
Stock compensation expense	14,917		14,917
Total other comprehensive loss	2,743			2,743
Net loss	(95,154)				(95,154)
Ending Balances at Dec. 31, 2017	199,549	$ 62	1,107,693	(881)	(907,325)
Ending Balances (in shares) at Dec. 31, 2017		61,533
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net	(523)	$ 1	(524)
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)		1,204
Issuance of common stock under Employee Stock Purchase Plan	594		594
Issuance of common stock under Employee Stock Purchase Plan (in shares)		125
Stock compensation expense	23,478		23,478
Total other comprehensive loss	(1,134)			(1,134)
Net loss	(158,899)				(158,899)
Ending Balances at Dec. 31, 2018	$ 63,065	$ 63	$ 1,131,241	$ (2,015)	$ (1,066,224)
Ending Balances (in shares) at Dec. 31, 2018		62,862

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities
Net loss	$ (158,899,000)	$ (95,154,000)	$ (112,444,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,621,000	3,244,000	2,257,000
Write-off of assets in progress			862,000
Loss (gain) on disposal of property and equipment	98,000	(10,000)	91,000
Accretion of discounts and amortization of premiums on marketable securities	(1,559,000)	(193,000)	178,000
Reversal of deferred rent upon lease amendment		(209,000)
Cash-settled portion of stock compensation expense	0	0	602,000
Stock compensation expense	23,478,000	14,917,000	14,126,000
Cost of sales - amortization of intangible assets	10,862,000	1,194,000
Non-cash interest expense	2,755,000
Changes in operating assets and liabilities:
Accounts and other receivables	(2,850,000)	488,000	52,000
Inventories, net	(18,710,000)	(312,000)
Prepaid expenses and other current assets	(2,405,000)	(1,830,000)	560,000
Other assets	(3,706,000)	(936,000)	(103,000)
Accounts payable	3,417,000	(1,915,000)	1,181,000
Accrued liabilities and other long term liabilities	12,597,000	3,198,000	(11,759,000)
Deferred revenues			(2,654,000)
Net cash used in operating activities	(131,301,000)	(77,518,000)	(107,051,000)
Investing activities
Acquisition of technology licenses	(11,000,000)
Purchases of marketable securities	(213,804,000)	(227,672,000)	(126,754,000)
Proceeds from maturities of marketable securities	284,457,000	119,638,000	220,760,000
Purchases of property and equipment, net	(4,187,000)	(669,000)	(7,757,000)
Net cash provided by (used in) investing activities	55,466,000	(108,703,000)	86,249,000
Financing activities
Proceeds from long-term debt, net	99,000,000
Proceeds from issuances of common stock, net		185,936,000
(Tax withholding) proceeds from exercise of stock options and restricted stock awards, net	(523,000)	1,613,000	(84,000)
Proceeds from Employee Stock Purchase Plan	594,000	293,000	615,000
Net cash provided by financing activities	99,071,000	187,842,000	531,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(482,000)	701,000	(259,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	22,754,000	2,322,000	(20,530,000)
Cash, cash equivalents and restricted cash at beginning of year	27,213,000	24,891,000	45,421,000
Cash, cash equivalents and restricted cash at end of year	49,967,000	27,213,000	24,891,000
Supplemental disclosure of cash flow information
Cash paid during the year for interest	6,583,000
Accrual for litigation settlement and insurance recovery (Note 9)			4,975,000
Release of accrual for litigation settlement and insurance recovery (Note 9)		4,975,000
Non-cash investing and financing activities:
Disposal of fully depreciated property and equipment	199,000	$ 86,000	2,354,000
Non-cash acquisition of technology license	$ 12,773,000
Astra Zeneca
Supplemental disclosure of cash flow information
Return of unused development funding to AstraZeneca AB			7,200,000
Milestone payment from AstraZeneca AB			$ 7,200,000

Organization

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization

1.	Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”), is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Our first commercial product, HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved by the United States Food and Drug Administration (“FDA”) for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. We commenced commercial shipments of HEPLISAV-B in January 2018. Our development efforts are primarily focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Our lead investigational immuno-oncology product candidates are SD-101, currently being evaluated in Phase 2 clinical studies, and DV281, in a Phase 1 safety study. We were incorporated in California in August 1996 under the name Double Helix Corporation, and we changed our name to Dynavax Technologies Corporation in September 1996. We reincorporated in Delaware in 2000.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include our accounts and those of our wholly-owned subsidiary, Dynavax GmbH located in Düsseldorf, Germany. All significant intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements. We operate in one business segment: the commercialization, discovery and development of biopharmaceutical products.

Liquidity and Financial Condition

As of December 31, 2018, we had cash, cash equivalents and marketable securities of $145.5 million.

We expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in commercialization of HEPLISAV-B, including investment in HEPLISAV-B inventory, clinical trials and other development, manufacturing and regulatory activities for our immuno-oncology product candidates, discovery research and development and tenant improvements and ongoing occupancy costs at our new corporate headquarters. Until we can generate a sufficient amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing arrangements and/or future public or private debt and equity financings. Adequate financing may not be available to us on acceptable terms, or at all.

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results could differ materially from these estimates.

Foreign Currency Translation

We consider the local currency to be the functional currency for our international subsidiary, Dynavax GmbH. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders’ equity. For the years ended December 31, 2018, 2017 and 2016, we reported an unrealized (loss) gain of $(1.1) million, $2.8 million and $(0.7) million, respectively. Realized gains and losses resulting from currency transactions are included in other income (expense) in the consolidated statements of operations. For the years ended December 31, 2018, 2017 and 2016, we reported a gain (loss) of $0.3 million, $(0.6) million and $0.2 million, respectively, resulting from currency transactions in our consolidated statements of operations.

Cash, Cash Equivalents and Marketable Securities

We consider all liquid investments purchased with an original maturity of three months or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.

We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

•

whether the investment has been in a continuous realized loss position for over 12 months;

•

the duration to maturity of our investments;

•

our intention and ability to hold the investment to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.

Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any losses on our cash equivalents and marketable securities.

Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts as described further below. We estimate our allowance for doubtful accounts based on an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have not recorded any allowance for doubtful accounts.

Our product candidates will require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process.

We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.

During the year ended December 31, 2018, 2017 and 2016, 83%, 90% and 92%, respectively, of our revenues were earned in the United States. As of December 31, 2018 and 2017, 24% and 15%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.

We have entered into distribution agreements with a limited number of wholesalers and specialty distributors in the U.S. All of our product revenue are to these customers. For the year ended and at December 31, 2018, respectively, our three largest customers represented approximately 68% of our product revenue and 71% of our trade receivable balance.

Inventories

Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. During 2018, we recorded $1.0 million in inventory reserves, which is included in cost of sales – product.

We primarily use actual costs to determine our cost basis for inventories. We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.

HEPLISAV-B was approved by the FDA on November 9, 2017, at which time we began to capitalize inventory costs associated with HEPLISAV-B. In March 2018, we received regulatory approval of the pre-filled syringe (“PFS”) presentation of HEPLISAV-B. Prior to FDA approval of HEPLISAV-B, all costs related to the manufacturing of HEPLISAV-B that could potentially be available to support the commercial launch of our products, were charged to research and development expense in the period incurred as there was no alternative future use. Prior to regulatory approval of PFS, costs associated with resuming operating activities at the Düsseldorf manufacturing facility were also included in research and development expense. Subsequent to regulatory approval of PFS, costs associated with operating activities at the Düsseldorf facility were included in cost of sales – product, until commercial production resumed in mid-2018 at which time these costs were recorded as raw materials inventory.

Intangible Assets

We record definite-lived intangible assets related to certain capitalized milestone and sublicense payments. After determining that the pattern of future cash flows associated with intangible asset could not be reliably estimated with a high level of precision, these assets are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life. We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. No impairment of intangible assets have been identified during the years presented.

Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.

We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. No impairments of tangible assets have been identified during the years presented.

Goodwill

Our goodwill balance relates to our April 2006 acquisition of Dynavax GmbH. Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. In performing its goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, we will proceed to perform a test for goodwill impairment. The first step involves comparing the estimated fair value of the related reporting unit against its carrying amount including goodwill. If the carrying amount exceeds the fair value, impairment is calculated and recorded as a charge in the consolidated statements of operations. We determined that we have only one operating segment and there are no components of that operating segment that are deemed to be separate reporting units such that we have one reporting unit for purposes of our goodwill impairment testing. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired. No impairments have been identified for the years presented.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification, (“ASC”) 606, Revenue from Contracts with Customers, using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Under the modified retrospective method, results for the reporting period beginning January 1, 2018 are presented under ASC 606, while the cumulative effect of initially applying the guidance is reflected as an adjustment to the opening balance of retained earnings at January 1, 2018. Adoption of this ASC did not have a material impact on our consolidated financial statements as there were no remaining performance obligations under our license and collaboration agreements as of the adoption date.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Revenue, Net

We sell our product to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our “Customers”). Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than one-year, there is no financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers’ inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. There have been no material adjustments to these estimates for the year ended December 31, 2018.

Product Returns: Consistent with industry practice, we offer our Customers a limited right of return based on the product’s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers’ inventory, shelf life of the product and other relevant factors.

Chargebacks: Our Customers subsequently resell our product to healthcare providers. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare provider by Customers, and we issue credits for such amounts generally within a few weeks of the Customer’s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to qualified healthcare providers, and chargebacks for units that our Customers have sold to healthcare providers, but for which credits have not been issued.

Trade Discounts and Allowances: We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.

Distribution Fees: Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.

Collaboration Revenue

We enter into collaborative arrangements with other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.

Research and Development Expenses and Accruals

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.

We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities through December 31, 2018.

Stock-Based Compensation

Stock-based compensation expense for restricted stock units and stock options is estimated at the grant date based on the award’s estimated fair value and is recognized on a straight-line basis over the award’s requisite service period, assuming estimated forfeiture rates. Fair value of restricted stock units is determined at the date of grant using the Company’s closing stock price. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.

Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation cost recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while giving consideration to options that have not yet completed a full life cycle. Stock-based compensation cost is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation cost could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.

Income Taxes

The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.

Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.

Significant judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting.

Based on our review, we concluded that it was more likely than not that we would not be able to realize the benefit of our domestic and foreign deferred tax assets in the future. This conclusion was based on historical and projected operating performance, as well as our expectation that our operations will not generate sufficient taxable income in future periods to realize the tax benefits associated with the deferred tax assets within the statutory carryover periods. Therefore, we have maintained a full valuation allowance on our deferred tax assets as of December 31, 2018 and 2017. We will continue to assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.

On December 22, 2017, President Trump signed U.S. tax reform legislation, commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”), which became effective January 1, 2018. The Tax Act significantly changed the fundamentals of U.S. corporate income taxation by, among many other things, reducing the U.S. federal corporate income tax rate to 21%, converting to a territorial tax system, and creating various income inclusion and expense limitation provisions. Also on December 22, 2017, The Securities and Exchange Commission staff issued Staff Accounting Bulletin (“SAB”) 118 to provide guidance for companies that are not able to complete their accounting for the income tax effects of the Tax Act in the period of enactment. SAB 118 provides for a measurement period of up to one year from the date of enactment. During the measurement period, companies need to reflect adjustments to any provisional amounts if it obtains, prepares or analyzes additional information about facts and circumstances that existed as of the enactment date that, if known, would have affected the income tax effects initially reported as provisional amounts. At December 31, 2018 we have completed our analysis of the Tax Act and there were no material changes or adjustments to the provisional amounts previously recorded.

Restructuring

Restructuring costs are comprised of severance costs related to workforce reductions. We recognize restructuring charges when the liability is incurred. Employee termination benefits are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments.

Recent Accounting Pronouncements

Accounting Standards Update 2016-02

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) which requires a lessee to recognize a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments, for all leases with a lease term greater than 12 months. In July 2018, the FASB issued ASU 2018-11, Targeted Improvements, which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. Also in July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 and elect the available practical expedients upon transition. We will elect the transition method that allows for the application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial statements. The new standard will have a material impact on our consolidated balance sheets, but will not have an impact on our consolidated statement of operations. Based on our preliminary analysis, the most significant impact will be the recognition of right-of-use asset and lease liabilities for operating leases ranging approximately from $34 million to $40 million on January 1, 2019. The amount of right-of-use asset and lease liabilities primarily relates to the corporate headquarters operating lease entered into in September 2018.

Accounting Standards Update 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.

Accounting Standards Update 2017-04

In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the test for goodwill impairment by eliminating a previous requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Accounting Standards Update 2018-13

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), that eliminates, adds and modifies certain disclosure requirements of fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Accounting Standards Update 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other –Internal-Use Software (Subtopic 350-40). This ASU requires a customer in a cloud computing arrangement (i.e. hosting arrangement) that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred. ASC 350-40 requires that certain costs incurred during the application development stage be capitalized and other costs incurred during the preliminary project and post-implementation stages be expensed as incurred. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Accounting Standards Update 2016-18

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force). This ASU requires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows include cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. The amendment in this update is applied using a retrospective transition method to each period presented. The ASU is effective for annual periods beginning after December 15, 2017. We adopted ASU 2016-18 on January 1, 2018 and have presented comparable prior period cash, cash equivalents and restricted cash balances in the consolidated statements of cash flows reflecting the retrospective impact of this ASU. See Note 4.

Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

•

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities;

•

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There were no transfers between Level 1 and Level 2 during the twelve months ended December 31, 2018 and 2017.

The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature.

As of December 31, 2018, we measured the fair value of our $7.0 million payment to Merck, Sharpe & Dohme Corp. (“Merck”), which is due in the first quarter of 2020, based on Level 3 inputs due to the use of unobservable inputs that cannot be corroborated by observable market data. We estimated the fair value of the liability using a discounted cash flow technique using the effective interest rate on our term loan. The liability had a fair value of $6.3 million as of December 31, 2018.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):

	Level 1		Level 2		Level 3		Total
December 31, 2018
Money market funds	$	44,002	$	-	$	-	$	44,002
U.S. treasuries		-		14,724		-		14,724
U.S. government agency securities		-		42,372		-		42,372
Corporate debt securities		-		41,291		-		41,291
Total	$	44,002	$	98,387	$	-	$	142,389

	Level 1		Level 2		Level 3		Total
December 31, 2017
Money market funds	$	22,543	$	-	$	-	$	22,543
U.S. treasuries		-		45,534		-		45,534
U.S. government agency securities		-		86,820		-		86,820
Corporate debt securities		-		32,916		-		32,916
Total	$	22,543	$	165,270	$	-	$	187,813

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

12 Months Ended

Dec. 31, 2018

Investments Debt And Equity Securities [Abstract]

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

4.	Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:

	December 31
	2018		2017		2016
Cash and cash equivalents	$	49,348	$	26,584	$	24,289
Restricted cash		619		629		602
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	49,967	$	27,213	$	24,891

Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our lease arrangements. See Note 9.

Cash, cash equivalents and marketable securities consist of the following (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2018
Cash and cash equivalents:
Cash	$	3,147	$	-	$	-		$	3,147
Money market funds		44,002		-		-			44,002
Corporate debt securities		2,199		-		-			2,199
Total cash and cash equivalents		49,348		-		-			49,348
Marketable securities available-for-sale:
U.S. treasuries		14,732		-		(8	)		14,724
U.S. government agency securities		42,416		-		(44	)		42,372
Corporate debt securities		39,108		-		(16	)		39,092
Total marketable securities available-for-sale		96,256		-		(68	)		96,188
Total cash, cash equivalents and marketable securities	$	145,604	$	-	$	(68	)	$	145,536
December 31, 2017
Cash and cash equivalents:
Cash	$	4,041	$	-	$	-		$	4,041
Money market funds		22,543		-		-			22,543
Total cash and cash equivalents		26,584		-		-			26,584
Marketable securities available-for-sale:
U.S. treasuries		45,559		-		(25	)		45,534
U.S. government agency securities		86,860		-		(40	)		86,820
Corporate debt securities		32,931		-		(15	)		32,916
Total marketable securities available-for-sale		165,350		-		(80	)		165,270
Total cash, cash equivalents and marketable securities	$	191,934	$	-	$	(80	)	$	191,854

The maturities of our marketable securities available-for-sale are as follows (in thousands):

.	December 31, 2018
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	96,256	$	96,188
Mature after one year through two years		-		-
	$	96,256	$	96,188

There were no realized gains or losses from the sale of marketable securities in the years ended December 31, 2018, 2017 and 2016. All of our investments are classified as short-term and available-for-sale, as we consider them available to fund current operations and may not hold our investments until maturity.

Inventories, Net

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories, net

5.	Inventories, net

The following table presents inventories (in thousands):

	December 31
	2018		2017
Raw materials	$	12,111	$	-
Work-in-process		6,562		312
Finished goods		349		-
Total	$	19,022	$	312

Intangible Assets, Net

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

6.	Intangible Assets, net

Intangible assets are related to certain capitalized milestone and sublicense payments. The following table presents intangible assets (in thousands):

	December 31,
	2018			2017
Intangible assets	$	19,773		$	2,500
Less accumulated amortization		(8,056	)		(1,194	)
Total	$	11,717		$	1,306

For the year ended December 31, 2018, we recorded $10.9 million in cost of sales - amortization of intangible assets which included amortization of $8.1 million, $1.5 million and $1.3 million related to capitalized milestone and sublicense payments to Merck, GlaxoSmithKline Biologicals SA (“GSK”) and Coley Pharmaceutical Group, Inc. (“Coley”), respectively. For the year ended December 31, 2017, we recorded $1.2 million in cost of sales - amortization of intangible assets related to a capitalized milestone payment to Coley. See Note 10. At December 31, 2018, the remaining intangible asset has an estimated remaining useful life of 16 months and will be fully amortized by April 2020. No impairment of intangible assets has been identified during the years presented.

Property and Equipment, Net

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Property and Equipment, Net

7.	Property and Equipment, net

Property and equipment consist of the following (in thousands):

	Estimated Useful	December 31,
	Life (In years)	2018			2017
Manufacturing equipment	5-14	$	12,029		$	12,104
Lab equipment	5-13		6,938			6,686
Computer equipment	3		5,465			4,760
Furniture and fixtures	3-13		1,809			1,629
Leasehold improvements	1-5		11,367			10,873
Assets in progress			2,605			1,176
			40,213			37,228
Less accumulated depreciation and amortization			(23,149	)		(20,609	)
Total		$	17,064		$	16,619

Depreciation and amortization expense on property and equipment was $3.6 million, $3.2 million and $2.3 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Current Accrued Liabilities and Accrued Research and Development

12 Months Ended

Dec. 31, 2018

Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]

Current Accrued Liabilities and Accrued Research and Development

8.	Current Accrued Liabilities and Accrued Research and Development

Current accrued liabilities and accrued research and development consist of the following (in thousands):

	December 31,
	2018		2017
Payroll and related expenses	$	8,058	$	6,180
Legal expenses		151		346
Revenue reserves liability		1,033		-
Third party research expenses		7,819		3,567
Third party development expenses		1,377		522
Other accrued liabilities		7,317		3,439
Total	$	25,755	$	14,054

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.	Commitments and Contingencies

We lease our facilities in Berkeley, California (“Berkeley Lease”), Emeryville, California and Düsseldorf, Germany (“Düsseldorf Lease”).

On September 17, 2018, we entered into an Office/Laboratory Lease (“Lease”) for office and laboratory space located at 5959 Horton Street, Emeryville, California (“Premises”). Under the terms of the Lease, we will lease 75,662 square feet in the Premises (“Rented Area”) at the rate of $4.75 (“Base Rate”) multiplied by the Rented Area, paid on a monthly basis, starting on the earlier of our commencement of our business operations at the Premises or April 1, 2019 (“Commencement Date”). The Base Rate is subject to scheduled annual increases, and we are also responsible for certain operating expenses and taxes throughout the life of the Lease. In connection with the Lease, we are entitled to a tenant improvement allowance of up to $8.3 million. The Lease has an initial term of 12 years, following the Commencement Date with an option to extend the lease for two successive five-year terms.

In connection with our execution of the Lease, on September 17, 2018, we entered into a Lease Termination Agreement to terminate the Berkeley Lease effective as of the date we vacate the Berkeley premises. The rent payable for the Berkeley Lease is subject to a “hold-over” increase should we not vacate prior to July 31, 2019.

Total net rent expense related to our operating leases for the years ended December 31, 2018, 2017 and 2016, was $4.0 million, $2.4 million and $2.2 million, respectively. Deferred rent was $2.3 million and $0.6 million as of December 31, 2018 and 2017, respectively.

In February 2018, we entered into a $175.0 million term loan agreement. Borrowings under the term loan agreement in the amount of $101.8 million is payable at maturity on December 31, 2023, unless earlier prepaid. See Note 11.

In February 2018, we entered into a sublicense agreement with Merck. Under the agreement, we are required to make future payments of $7.0 million each in both February 2019 and February 2020. See Note 10.

We have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B and SD-101. To the extent these commitments are non-cancelable, they are reflected in the table below.

Future payments under the term loan agreement, sublicense agreement, minimum payments under the non-cancelable portion of our operating leases and non-cancelable purchase commitments at December 31, 2018, are as follows (in thousands):

Year ending December 31,
2019	$	22,378
2020		12,256
2021		5,144
2022		5,212
2023		109,760
Thereafter		39,523
Total	$	194,273

During 2004, we established a letter of credit with Silicon Valley Bank as security for our Berkeley Lease in the amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2018, and is collateralized by a certificate of deposit for $0.4 million, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2018 and 2017. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.

During 2004, we also established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the amount of 0.2 million Euros. The letter of credit remained outstanding through December 31, 2018 and is collateralized by a certificate of deposit for 0.2 million Euros, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2018 and 2017.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.

We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.

In conjunction with a financing arrangement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (“Holdings”) in November 2009, we agreed to make contingent cash payments to Holdings equal to 50% of the first $50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including SD-101. We have made no payments and have not recorded a liability as of December 31, 2018 and 2017.

From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, financial statements, results of operations, or cash flows in a particular period.

On September 7, 2016, we entered into a Stipulation of Settlement to settle the case entitled In re Dynavax Technologies Securities Litigation filed in 2013. The settlement, which was approved by the U.S. District Court for the Northern District of California on February 6, 2017, provided for a payment of $4.1 million by us and results in a dismissal and release of all claims against all defendants, including us. The settlement was paid by our insurers in February 2017.

On October 24, 2017, we entered into a Stipulation of Settlement to settle the derivative case filed in 2013. The settlement provided for a payment of $0.9 million by us and results in a dismissal and release of all claims against all defendants, including us. The settlement was paid by our insurers in November 2017.

Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Use of Estimates in Note 2.

Collaborative Research, Development and License Agreements

12 Months Ended

Dec. 31, 2018

Research And Development [Abstract]

Collaborative Research, Development and License Agreements

10.	Collaborative Research, Development and License Agreements

AstraZeneca

Pursuant to a research collaboration and license agreement with AstraZeneca AB (AstraZeneca”), as amended, we discovered and performed initial clinical development of AZD1419, a TLR9 agonist product candidate for the treatment of asthma. In June 2016, all of our remaining performance obligations under our agreement with AstraZeneca were completed and we recognized collaboration revenue of $9.8 million. In November 2018, we were informed by AstraZeneca that initial results from the Phase 2a study indicate AZD1419 treatment did not meet the primary endpoint of the study. AstraZeneca is reviewing the full data before deciding on the next steps for the AZD1419 program.

Serum Institute of India Pvt. Ltd.

In June 2017, we entered into an agreement to provide Serum Institute of India Pvt. Ltd. (“SIIPL”) with technical support. In consideration, SIIPL agreed to pay us at an agreed upon hourly rate for services and reimburse certain out-of-pocket expenses. In addition, we have rights to commercialization of certain potential products manufactured at the SIIPL facility. During the fourth quarter of 2018, we recognized collaboration revenue for services performed through December 31, 2018.

Merck, Sharp & Dohme Corp.

In February 2018, we entered into a Sublicense Agreement (the “Sublicense Agreement”) with Merck. The Sublicense Agreement grants us, under certain non-exclusive U.S. patent rights controlled by Merck which relate to recombinant production of hepatitis B surface antigen, the right to manufacture, use, offer for sale, sell and import HEPLISAV-B in the United States and includes the right to grant further sublicenses. Under the terms of the Sublicense Agreement, we are obligated to pay $21.0 million in three installments. The first installment of $7.0 million was paid in February 2018 and the remaining two payments of $7.0 million each are due in the first quarter of each of 2019 and 2020. The payments in 2019 and 2020 are classified on the condensed consolidated balance sheets as other current liabilities and other long-term liabilities, respectively. In February 2018, we recorded $19.8 million as an intangible asset. At December 31, 2018, the intangible asset, net balance was $11.7 million. See Note 6. The agreement continues in effect through April 2020, at which time the license becomes perpetual, irrevocable, fully paid-up and royalty free.

GlaxoSmithKline Biologicals SA

On July 12, 2018, we entered into a sublicense agreement with GSK. The GSK sublicense agreement grants us, under certain non-exclusive U.S. patent rights controlled by GSK, the right to manufacture, use, offer to sell, sell and import HEPLISAV-B in the United States and includes the right to grant further sublicenses. In consideration, we paid a $1.5 million license fee to GSK in July 2018 and recorded this payment as an intangible asset. At December 31, 2018, the intangible asset has been fully amortized. See Note 6. In addition, we were obligated to pay GSK, royalties of 13% of net sales of HEPLISAV-B from December 1, 2017 through July 31, 2018. For the year ended December 31, 2018, we recorded $0.2 million of royalties in cost of sales – product in the condensed consolidated statements of operations.

Coley Pharmaceutical Group, Inc.

In June 2007, we entered into a license agreement with Coley, under which Coley granted us a non-exclusive, royalty bearing license to patents, with the right to grant sublicenses for HEPLISAV-B (the “Coley Agreement). We met one of the regulatory milestones upon FDA approval of HEPLISAV-B in November 2017 and paid $2.5 million in January 2018 to Coley which was recorded as an intangible asset on the consolidated balance sheets. See Note 6. The Coley Agreement terminated in February 2018, at which time the license became a perpetual, irrevocable, fully paid-up and royalty free license. As of December 31, 2018, the $2.5 million intangible asset has been fully amortized.

Long-Term Debt

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt

11.	Long-Term Debt

Long-Term Debt

On February 20, 2018, we entered into a $175.0 million term loan agreement (“Loan Agreement”) with CRG Servicing LLC. The Loan Agreement provides for a $175.0 million term loan facility, $100.0 million of which was borrowed at closing (“Initial Term Loan”) and, subject to the satisfaction of certain market capitalization and other borrowing conditions, up to an additional $75.0 million is available for borrowing at our option on or before July 17, 2019 (together with the Initial Term Loan, the “Term Loans”). Net proceeds from the Initial Term Loan were $99.0 million. The Term Loans under the Loan Agreement bear interest at a rate equal to 9.5% per annum. At December 31, 2018, the effective interest rate was 10.1%. At our option, until September 30, 2023, a portion of the interest payments may be paid in kind, and thereby added to the principal. Through December 31, 2018, a portion of our interest was paid in kind, which increased the principal amount of the Term Loans to $101.8 million. The Term Loans have a maturity date of December 31, 2023, unless earlier prepaid. The Term Loans and paid-in-kind interest will be entirely payable at maturity.

The obligations under the Loan Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Company and any future subsidiary guarantors, except for certain customary excluded property, and (ii) all of the capital stock owned by the Company and such future subsidiary guarantors (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and certain U.S. subsidiaries substantially all of whose assets consist of equity interests in non-U.S. subsidiaries, to 65% of the capital stock of such subsidiaries, subject to certain exceptions). The obligations under the Loan Agreement will be guaranteed by each of the Company’s future direct and indirect subsidiaries (other than certain non-U.S. subsidiaries of the Company and certain U.S. subsidiaries substantially all of whose assets consist of equity interests in non-U.S. subsidiaries, subject to certain exceptions). The Loan Agreement contains customary covenants and requires us to comply with a $15.0 million daily minimum combined cash and investment balance covenant and an annual revenue requirement starting in 2019 for sales of HEPLISAV-B.

The Term Loans may be prepaid by us at any time. If the Term Loans are prepaid prior to the second anniversary of the initial borrowing date, we are subject to a repayment premium of up to 7.0% of the principal amount prepaid, depending on the date of prepayment.

We recorded $8.8 million of interest expense related to the Initial Term Loan during the year ended December 31, 2018.

Note Purchase Agreement

In October 2016, we entered into a Note Purchase Agreement pursuant to which the Company would borrow $100.0 million upon approval of HEPLISAV-B. The Company paid the prospective lender $1.0 million upon entering into the Note Purchase Agreement and incurred additional expenses of $1.6 million in securing the Note Purchase Agreement. No notes were ultimately sold by the Company under the Note Purchase Agreement.

In December 2016, the Company terminated the Note Purchase Agreement and paid a termination fee of $1.5 million. The $1.0 million paid upon entering in the note purchase agreement and $1.5 million termination fee are included in other expense in the consolidated statements of operations. The additional expenses of $1.6 million related to securing the Note Purchase Agreement are included in loss from operations in the consolidated statement of operations.

Revenue Recognition

12 Months Ended

Dec. 31, 2018

Revenue Recognition [Abstract]

Revenue Recognition

12.	Revenue Recognition

Our source of product revenue for the year ended December 31, 2018, consists of sales of HEPLISAV-B in the U.S. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the year ended December 31, 2018 (in thousands):

	Chargebacks, discounts and other fees			Returns			Total
Balance at December 31, 2017	$	-		$	-		$	-
Provision related to current period sales		4,012			570			4,582
Credit or payments made during the period		(2,276	)		(1	)		(2,277	)
Balance at December 31, 2018	$	1,736		$	569		$	2,305

At December 31, 2018, reserves for chargebacks and discounts totaling $1.3 million were recorded as reductions of accounts receivable while the remaining reserves balances totaling $1.0 million were recorded as accrued liabilities in the condensed consolidated balance sheets.

Net Loss Per Share

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Net Loss Per Share

13.	Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period and giving effect to all potentially dilutive common shares using the treasury-stock method. For purposes of this calculation, outstanding stock options and stock awards are considered to be potentially dilutive common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive.

	December 31,
	2018			2017			2016
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss	$	(158,899	)	$	(95,154	)	$	(112,444	)
Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		62,362			52,613			38,506
Basic and diluted net loss per share	$	(2.55	)	$	(1.81	)	$	(2.92	)

Outstanding stock options and stock awards were excluded from the calculation of net loss per share allocable to common stockholders as the effect of their inclusion would have been anti-dilutive.

	December 31,
	2018		2017		2016
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		7,344		5,981		4,673

Common Stock

12 Months Ended

Dec. 31, 2018

Preferred Stock Common Stock And Warrants [Abstract]

Common Stock

14.	Common Stock

Common Stock Outstanding

As of December 31, 2018, there were 62,862,478 shares of our common stock outstanding.

On November 3, 2017, we entered into an At Market Sales Agreement (“2017 ATM Agreement”) with Cowen and Company, LLC (“Cowen”) under which we may offer and sell from time to time at our sole discretion, shares of our common stock having an aggregate offering price up to $150 million through Cowen as our sales agent. We pay Cowen a commission of up to 3% of the gross sales proceeds of any common stock sold through Cowen under the 2017 ATM Agreement. For the year ended December 31, 2017, we received net cash proceeds of $16.9 million resulting from sales of 840,774 shares of our common stock. As of December 31, 2018, we have $132.8 million remaining under the 2017 ATM Agreement. Subsequent to December 31, 2018 and through February 22, 2019, we sold 1,078,901 shares of common stock for net proceeds of $11.5 million under the 2017 ATM Agreement.

In August 2017, we completed an underwritten public offering of 5,750,000 shares of our common stock, including 750,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered at a price to the public of $15.00 per share. The net proceeds to us from this offering were approximately $80.8 million, after deducting the underwriting discount and other estimated offering expenses payable by us.

As of December 31, 2017, we received net cash proceeds of $88.2 million from sales of 15,997,202 shares of our common stock under a now terminated At Market Sales Agreement.

Equity Plans and Stock-Based Compensation

12 Months Ended

Dec. 31, 2018

Share Based Compensation [Abstract]

Equity Plans and Stock-Based Compensation

15.	Equity Plans and Stock-Based Compensation

Stock Plans

On May 31, 2018, our stockholders approved the 2018 Equity Incentive Plan (the “2018 EIP”). The 2018 EIP is intended to be the successor to the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the “2011 EIP”). The aggregate number of shares of our common stock that may be issued under the 2018 EIP (subject to adjustment for certain changes in capitalization) is comprised of the sum of (i) 5,000,000 newly reserved shares of common stock, (ii) 140,250 unallocated shares of common stock remaining available for grant under the 2011 EIP as of May 31, 2018, and (iii) 7,477,619 shares subject to outstanding stock awards granted under the 2011 EIP and the Dynavax Technologies Corporation 2017 Inducement Award Plan that may become available from time to time as set forth in the 2018 EIP. The 2018 EIP provides for the issuance of up to 12,617,869 shares of our common stock to employees of the Company. The 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the 2018 EIP have a term of 7 years unless earlier terminated by the Board of Directors. As of December 31, 2018, options to purchase 5,750,404 shares of common stock remained outstanding under the 2018 EIP. As of December 31, 2018, there were 4,810,112 shares of common stock reserved for issuance under the 2018 EIP.

Activity under our stock plans is set forth below:

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2017		3,555		$	19.56
Options granted		2,503			16.30
Options exercised		(42	)		11.80
Options cancelled:
Options forfeited (unvested)		(178	)		14.29
Options expired (vested)		(88	)		29.58
Balance at December 31, 2018		5,750		$	18.20		5.47	$	651
Vested and expected to vest at December 31, 2018		5,534		$	18.28		5.44	$	644
Exercisable at December 31, 2018		2,975		$	19.90		4.87	$	466

The total intrinsic value of stock options exercised during the years ended December 31, 2018, 2017 and 2016 was $0.2 million, $0.9 million and $0.2 million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.

The total fair value of stock options vested during the years ended December 31, 2018, 2017 and 2016 was $8.1 million, $13.0 million and $12.1 million, respectively.

Our non-vested stock awards are comprised of restricted stock units granted with performance and time-based vesting criteria. A summary of the status of non-vested restricted stock units as of December 31, 2018, and activities during 2018 are summarized as follows:

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2017		2,443		$	6.01
Granted		458			15.98
Vested		(1,219	)		5.86
Forfeited		(88	)		9.07
Non-vested as of December 31, 2018		1,594		$	8.82

Stock-based compensation expense related to restricted stock units was approximately $8.4 million for the year ended December 31, 2018. The aggregate intrinsic value of the restricted stock units outstanding as of December 31, 2018, based on our stock price on that date, was $14.6 million.

The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2018, 2017 and 2016 was, $15.98, $5.34 and $12.42, respectively. The total fair value of restricted stock units vested during the years ended December 31, 2018, 2017 and 2016 was $19.4 million, $1.2 million and $1.0 million, respectively.

Stock-Based Compensation

Under our stock-based compensation plans, option awards generally vest over a three-year or four-year period contingent upon continuous service and unless exercised, expire seven or ten years from the date of grant (or earlier upon termination of continuous service). The Company has also granted performance-based equity awards to certain of our employees. As of December 31, 2018, approximately 151,000 shares underlying stock options and approximately 12,500 restricted stock unit awards with performance-based vesting criteria were outstanding. Vesting criteria for 5,000 of the awards with performance-based vesting criteria were not probable as of December 31, 2018. We recognized stock-based compensation expense for awards with performance-based vesting criteria during the years ended December 31, 2018, 2017 and 2016 of $1.9 million, $0.3 million and $0.5 million, respectively.

The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:

	Stock Options									Employee Stock Purchase Plan
	Year Ended December 31,									Year Ended December 31,
	2018			2017			2016			2018			2017			2016
Weighted-average fair value	$	10.75		$	8.27		$	9.54		$	8.30		$	3.05		$	7.86
Risk-free interest rate		2.5	%		1.9	%		1.4	%		2.4	%		1.0	%		0.6	%
Expected life (in years)		4.2			4.5			4.9			1.3			1.2			1.2
Expected Volatility		0.8			0.9			0.7			1.1			1.0			0.6

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Forfeiture estimates are based on historical employee turnover. The dividend yield is zero percent for all years and is based on our history and expectation of dividend payouts.

Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.

We recognized the following amounts of stock-based compensation expense (in thousands):

	Year Ended December 31,
	2018		2017		2016
Employees and directors stock-based compensation expense	$	23,478	$	14,917	$	14,126

	Year Ended December 31,
	2018		2017		2016
Research and development	$	9,604	$	7,827	$	6,742
Selling, general and administrative		11,761		7,090		7,384
Cost of sales - product		1,354		-		-
Inventory		759		-		-
Total	$	23,478	$	14,917	$	14,126

In addition, the cash-settled portion of stock compensation expense was $0.6 million for the year ended December 31, 2016. No cash-settled portion of stock compensation expense was incurred during 2017 or 2018.

As of December 31, 2018, the total unrecognized compensation cost related to non-vested stock options and awards deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $26.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.9 years. Additionally, as of December 31, 2018, the total unrecognized compensation cost related to equity awards with performance-based vesting criteria amounted to $0.3 million.

Employee Stock Purchase Plan

The Amended and Restated 2014 Employee Stock Purchase Plan (the “Purchase Plan”) provides for the purchase of common stock by eligible employees and became effective on May 28, 2014. On May 31, 2018, our stockholders approved an amendment to the Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance by 600,000 shares. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the commencement of the offer period (generally, the sixteenth day in February or August) or (ii) 85% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). For the year ended December 31, 2018, employees have acquired 125,193 shares of our common stock under the Purchase Plan and 573,034 shares of our common stock remained available for future purchases under the Purchase Plan.

As of December 31, 2018, the total unrecognized compensation cost related to shares of our common stock under the Purchase Plan amounted to $0.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.6 years.

Employee Benefit Plan

12 Months Ended

Dec. 31, 2018

Pension And Other Postretirement Benefit Expense [Abstract]

Employee Benefit Plan

16.	Employee Benefit Plan

We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our discretion, contribute for the benefit of eligible employees. The Company’s contribution to the 401(k) Plan was approximately $0.2 million for each of the years ended December 31, 2018, 2017 and 2016.

Restructuring

12 Months Ended

Dec. 31, 2018

Restructuring And Related Activities [Abstract]

Restructuring

17.	Restructuring

In January 2017, we implemented organizational restructuring and cost reduction plans to align around our immuno-oncology business while allowing us to advance HEPLISAV-B through the FDA review and approval process. To achieve these cost reductions, we suspended manufacturing activities, commercial preparations and other long term investment related to HEPLISAV-B and reduced our global workforce by approximately 40 percent. In the first quarter of 2017 we recorded charges of $2.8 million related to severance, other termination benefits and outplacement services. All of the $2.8 million was paid in 2017.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

18.	Income Taxes

Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):

	Year Ended December 31,
	2018			2017			2016
U.S.	$	(160,032	)	$	(95,898	)	$	(114,484	)
Non U.S.		1,133			744			2,040
Total	$	(158,899	)	$	(95,154	)	$	(112,444	)

No income tax expense was recorded for the years ended December 31, 2018, 2017 and 2016 due to our full valuation allowance position. The difference between the consolidated income tax benefit and the amount computed by applying the federal statutory income tax rate to the consolidated loss before income taxes was as follows (in thousands):

	Year Ended December 31,
	2018			2017			2016
Income tax benefit at federal statutory rate	$	(33,366	)	$	(32,352	)	$	(38,183	)
State tax		(5,591	)		(4,482	)		(334	)
Business credits		(3,065	)		(1,960	)		(1,950	)
Deferred compensation charges		(1,165	)		3,823			3,016
Change in valuation allowance		43,134			(109,165	)		36,751
Rate change		-			86,943			-
Net operating loss and tax credit limitation		-			56,962			-
Other		53			231			700
Total income tax expense	$	-		$	-		$	-

Deferred tax assets and liabilities consisted of the following (in thousands):

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carry forwards	$	178,730		$	146,300
Research tax credit carry forwards		34,064			29,658
Accruals and reserves		10,137			6,551
Capitalized research costs		943			1,422
Other		1,147			731
Total deferred tax assets		225,021			184,662
Less valuation allowance		(224,746	)		(184,388	)
Net deferred tax assets		275			274
Deferred tax liabilities:
Fixed assets		(275	)		(274	)
Total deferred tax liabilities		(275	)		(274	)
Net deferred tax assets	$	-		$	-

The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $40.4 million during the year ended December 31, 2018 due to an increase in our deferred tax assets and decreased by $108.8 million during the year ended December 31, 2017 primarily as a result of the reduction in our deferred tax assets resulting from the decrease in the U.S. federal statutory tax rate.

Also on December 22, 2017, The Securities and Exchange Commission staff issued Staff Accounting Bulletin (“SAB”) 118 to provide guidance for companies that are not able to complete their accounting for the income tax effects of the Tax Act in the period of enactment. SAB 118 provides for a measurement period of up to one year from the date of enactment. During the measurement period, companies need to reflect adjustments to any provisional amounts if it obtains, prepares or analyzes additional information about facts and circumstances that existed as of the enactment date that, if known, would have affected the income tax effects initially reported as provisional amounts.

At December 31, 2018 we have completed our analysis of the Tax Act. The Act included a re-measurement of our net U.S. deferred tax assets reducing the U.S. federal corporate rate to 21%, which was offset by a valuation allowance. During 2018, this amount was finalized and no additional adjustment was required due to the change in corporate tax rate.

The one-time transition tax is based on our total post-1986 earnings and profits that we previously deferred from U.S. income taxes. In 2017 we recorded a provisional amount for our one-time transition tax liability for our foreign subsidiaries. In 2018 the transition tax calculation was completed. The transition tax that we calculated resulted in an immaterial reduction income from the provisional amount recorded in 2017.

Also effective for 2018 is a new Global Intangible Low-Taxed Income inclusion (“GILTI”). The GILTI income inclusion did not have a material impact on our 2018 current loss or valuation allowance position. We elected to account for GILTI as a period cost in the year the income or tax is incurred.

As of December 31, 2018, we had federal net operating loss carryforwards of approximately $771.8 million, which will begin to expire in the year 2019 and federal research and development tax credits of approximately $19.9 million, which expire in the years 2019 through 2038.

As of December 31, 2018, we had net operating loss carryforwards for California and other states for income tax purposes of approximately $229.0 million, which expire in the years 2019 through 2038, and California state research and development tax credits of approximately $19.1 million, which do not expire.

As of December 31, 2018, we had net operating loss carryforwards for foreign income tax purposes of approximately $11.9 million, which do not expire.

Uncertain Income Tax positions

The total amount of unrecognized tax benefits was $1.2 million as of each of the years ended December 31, 2018 and 2017. If recognized, none of the unrecognized tax benefits would affect the effective tax rate.

The following table summarizes the activity related to our unrecognized tax benefits:

Balance at December 31, 2017	$	(1,229	)
Tax positions related to the current year
Additions		-
Reductions		-
Tax positions related to the prior year
Additions		-
Reductions		-
Balance at December 31, 2018	$	(1,229	)

Our policy is to account for interest and penalties as income tax expense. As of December 31, 2018, there was no interest related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions.

The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event there is a change in ownership, as defined, the annual utilization of such carryforwards could be limited. Based on an analysis under Section 382 of the Internal Revenue Code, completed through December 31, 2018, we experienced ownership changes in 2008, 2009 and 2012 which limit the future use of its pre-change federal net operating loss carryforwards and federal research and development tax credits. We excluded these federal net operating loss carryforwards and federal research and development tax credits that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2018. A limitation calculation has not been performed with respect to the California net operating loss carryforwards and research and development tax credits and we believe that our ability to use these California net operating loss carryforwards and research and development tax credits in the future may be limited.

We are subject to income tax examinations for U.S. federal and state income taxes from 1999 forward. We are subject to tax examination in Germany from 2017 forward and in India from 2018 forward.

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

19.	Selected Quarterly Financial Data (Unaudited; in thousands, except per share amounts)

	Year Ended December 31, 2018
	Q1			Q2			Q3			Q4
Total revenues	$	165		$	1,254		$	1,461		$	5,318
Net loss	$	(38,958	)	$	(39,444	)	$	(40,528	)	$	(39,969	)
Basic and diluted net loss per share	$	(0.63	)	$	(0.63	)	$	(0.65	)	$	(0.64	)
Shares used to compute basic and diluted net loss per share		61,744			62,346			62,650			62,694

	Year Ended December 31, 2017
	Q1			Q2			Q3			Q4
Total revenues	$	148		$	105		$	53		$	21
Net loss	$	(25,287	)	$	(20,318	)	$	(22,128	)	$	(27,421	)
Basic and diluted net loss per share	$	(0.60	)	$	(0.41	)	$	(0.38	)	$	(0.45	)
Shares used to compute basic and diluted net loss per share		41,830			49,700			57,650			61,007

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Liquidity and Financial Condition

As of December 31, 2018, we had cash, cash equivalents and marketable securities of $145.5 million.

Use of Estimates

Foreign Currency Translation

Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

•

whether the investment has been in a continuous realized loss position for over 12 months;

•

the duration to maturity of our investments;

•

our intention and ability to hold the investment to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.

Product Revenue, Net

Reserves for Variable Consideration

Collaboration Revenue

Research and Development Expenses and Accruals

Stock-Based Compensation

Income Taxes

Restructuring

Recent Accounting Pronouncements

Accounting Standards Update 2016-02

Accounting Standards Update 2016-13

Accounting Standards Update 2017-04

Accounting Standards Update 2018-13

Accounting Standards Update 2018-15

Accounting Standards Update 2016-18

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):

	Level 1		Level 2		Level 3		Total
December 31, 2018
Money market funds	$	44,002	$	-	$	-	$	44,002
U.S. treasuries		-		14,724		-		14,724
U.S. government agency securities		-		42,372		-		42,372
Corporate debt securities		-		41,291		-		41,291
Total	$	44,002	$	98,387	$	-	$	142,389

	Level 1		Level 2		Level 3		Total
December 31, 2017
Money market funds	$	22,543	$	-	$	-	$	22,543
U.S. treasuries		-		45,534		-		45,534
U.S. government agency securities		-		86,820		-		86,820
Corporate debt securities		-		32,916		-		32,916
Total	$	22,543	$	165,270	$	-	$	187,813

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2018

Cash Cash Equivalents And Short Term Investments [Abstract]

Reconciliation of Cash, Cash Equivalents and Restricted Cash

	December 31
	2018		2017		2016
Cash and cash equivalents	$	49,348	$	26,584	$	24,289
Restricted cash		619		629		602
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	49,967	$	27,213	$	24,891

Summary of Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities consist of the following (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2018
Cash and cash equivalents:
Cash	$	3,147	$	-	$	-		$	3,147
Money market funds		44,002		-		-			44,002
Corporate debt securities		2,199		-		-			2,199
Total cash and cash equivalents		49,348		-		-			49,348
Marketable securities available-for-sale:
U.S. treasuries		14,732		-		(8	)		14,724
U.S. government agency securities		42,416		-		(44	)		42,372
Corporate debt securities		39,108		-		(16	)		39,092
Total marketable securities available-for-sale		96,256		-		(68	)		96,188
Total cash, cash equivalents and marketable securities	$	145,604	$	-	$	(68	)	$	145,536
December 31, 2017
Cash and cash equivalents:
Cash	$	4,041	$	-	$	-		$	4,041
Money market funds		22,543		-		-			22,543
Total cash and cash equivalents		26,584		-		-			26,584
Marketable securities available-for-sale:
U.S. treasuries		45,559		-		(25	)		45,534
U.S. government agency securities		86,860		-		(40	)		86,820
Corporate debt securities		32,931		-		(15	)		32,916
Total marketable securities available-for-sale		165,350		-		(80	)		165,270
Total cash, cash equivalents and marketable securities	$	191,934	$	-	$	(80	)	$	191,854

Maturities of Marketable Securities Available-for-Sale

The maturities of our marketable securities available-for-sale are as follows (in thousands):

.	December 31, 2018
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	96,256	$	96,188
Mature after one year through two years		-		-
	$	96,256	$	96,188

Inventories, Net (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Summary of Inventories

The following table presents inventories (in thousands):

	December 31
	2018		2017
Raw materials	$	12,111	$	-
Work-in-process		6,562		312
Finished goods		349		-
Total	$	19,022	$	312

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets, Net

Intangible assets are related to certain capitalized milestone and sublicense payments. The following table presents intangible assets (in thousands):

	December 31,
	2018			2017
Intangible assets	$	19,773		$	2,500
Less accumulated amortization		(8,056	)		(1,194	)
Total	$	11,717		$	1,306

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Component of Property and Equipment, Net

Property and equipment consist of the following (in thousands):

	Estimated Useful	December 31,
	Life (In years)	2018			2017
Manufacturing equipment	5-14	$	12,029		$	12,104
Lab equipment	5-13		6,938			6,686
Computer equipment	3		5,465			4,760
Furniture and fixtures	3-13		1,809			1,629
Leasehold improvements	1-5		11,367			10,873
Assets in progress			2,605			1,176
			40,213			37,228
Less accumulated depreciation and amortization			(23,149	)		(20,609	)
Total		$	17,064		$	16,619

Current Accrued Liabilities and Accrued Research and Development (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]

Component of Current Accrued Liabilities and Accrued Research and Development

Current accrued liabilities and accrued research and development consist of the following (in thousands):

	December 31,
	2018		2017
Payroll and related expenses	$	8,058	$	6,180
Legal expenses		151		346
Revenue reserves liability		1,033		-
Third party research expenses		7,819		3,567
Third party development expenses		1,377		522
Other accrued liabilities		7,317		3,439
Total	$	25,755	$	14,054

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Term Loan and Sublicense Agreement

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases and Non-Cancelable Purchase Commitments

Year ending December 31,
2019	$	22,378
2020		12,256
2021		5,144
2022		5,212
2023		109,760
Thereafter		39,523
Total	$	194,273

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2018

Revenue Recognition [Abstract]

Summary of Product Revenue Allowance and Reserve Categories

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the year ended December 31, 2018 (in thousands):

	Chargebacks, discounts and other fees			Returns			Total
Balance at December 31, 2017	$	-		$	-		$	-
Provision related to current period sales		4,012			570			4,582
Credit or payments made during the period		(2,276	)		(1	)		(2,277	)
Balance at December 31, 2018	$	1,736		$	569		$	2,305

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

	December 31,
	2018			2017			2016
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss	$	(158,899	)	$	(95,154	)	$	(112,444	)
Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		62,362			52,613			38,506
Basic and diluted net loss per share	$	(2.55	)	$	(1.81	)	$	(2.92	)

	December 31,
	2018		2017		2016
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		7,344		5,981		4,673

Equity Plans and Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Share Based Compensation [Abstract]

Option Activity under Stock-Based Compensation Plans

Activity under our stock plans is set forth below:

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2017		3,555		$	19.56
Options granted		2,503			16.30
Options exercised		(42	)		11.80
Options cancelled:
Options forfeited (unvested)		(178	)		14.29
Options expired (vested)		(88	)		29.58
Balance at December 31, 2018		5,750		$	18.20		5.47	$	651
Vested and expected to vest at December 31, 2018		5,534		$	18.28		5.44	$	644
Exercisable at December 31, 2018		2,975		$	19.90		4.87	$	466

Summary of Non-vested Restricted Stock Units Activity

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2017		2,443		$	6.01
Granted		458			15.98
Vested		(1,219	)		5.86
Forfeited		(88	)		9.07
Non-vested as of December 31, 2018		1,594		$	8.82

Fair Value-Based Measurements and Weighted-Average Assumptions

The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:

	Stock Options									Employee Stock Purchase Plan
	Year Ended December 31,									Year Ended December 31,
	2018			2017			2016			2018			2017			2016
Weighted-average fair value	$	10.75		$	8.27		$	9.54		$	8.30		$	3.05		$	7.86
Risk-free interest rate		2.5	%		1.9	%		1.4	%		2.4	%		1.0	%		0.6	%
Expected life (in years)		4.2			4.5			4.9			1.3			1.2			1.2
Expected Volatility		0.8			0.9			0.7			1.1			1.0			0.6

Stock-Based Compensation Expense

We recognized the following amounts of stock-based compensation expense (in thousands):

	Year Ended December 31,
	2018		2017		2016
Employees and directors stock-based compensation expense	$	23,478	$	14,917	$	14,126

	Year Ended December 31,
	2018		2017		2016
Research and development	$	9,604	$	7,827	$	6,742
Selling, general and administrative		11,761		7,090		7,384
Cost of sales - product		1,354		-		-
Inventory		759		-		-
Total	$	23,478	$	14,917	$	14,126

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Component of Consolidated (Loss) Income Before Provision for Income Taxes

Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):

	Year Ended December 31,
	2018			2017			2016
U.S.	$	(160,032	)	$	(95,898	)	$	(114,484	)
Non U.S.		1,133			744			2,040
Total	$	(158,899	)	$	(95,154	)	$	(112,444	)

Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate

	Year Ended December 31,
	2018			2017			2016
Income tax benefit at federal statutory rate	$	(33,366	)	$	(32,352	)	$	(38,183	)
State tax		(5,591	)		(4,482	)		(334	)
Business credits		(3,065	)		(1,960	)		(1,950	)
Deferred compensation charges		(1,165	)		3,823			3,016
Change in valuation allowance		43,134			(109,165	)		36,751
Rate change		-			86,943			-
Net operating loss and tax credit limitation		-			56,962			-
Other		53			231			700
Total income tax expense	$	-		$	-		$	-

Component of Deferred Tax Assets and Liabilities

Deferred tax assets and liabilities consisted of the following (in thousands):

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carry forwards	$	178,730		$	146,300
Research tax credit carry forwards		34,064			29,658
Accruals and reserves		10,137			6,551
Capitalized research costs		943			1,422
Other		1,147			731
Total deferred tax assets		225,021			184,662
Less valuation allowance		(224,746	)		(184,388	)
Net deferred tax assets		275			274
Deferred tax liabilities:
Fixed assets		(275	)		(274	)
Total deferred tax liabilities		(275	)		(274	)
Net deferred tax assets	$	-		$	-

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity related to our unrecognized tax benefits:

Balance at December 31, 2017	$	(1,229	)
Tax positions related to the current year
Additions		-
Reductions		-
Tax positions related to the prior year
Additions		-
Reductions		-
Balance at December 31, 2018	$	(1,229	)

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

	Year Ended December 31, 2018
	Q1			Q2			Q3			Q4
Total revenues	$	165		$	1,254		$	1,461		$	5,318
Net loss	$	(38,958	)	$	(39,444	)	$	(40,528	)	$	(39,969	)
Basic and diluted net loss per share	$	(0.63	)	$	(0.63	)	$	(0.65	)	$	(0.64	)
Shares used to compute basic and diluted net loss per share		61,744			62,346			62,650			62,694

	Year Ended December 31, 2017
	Q1			Q2			Q3			Q4
Total revenues	$	148		$	105		$	53		$	21
Net loss	$	(25,287	)	$	(20,318	)	$	(22,128	)	$	(27,421	)
Basic and diluted net loss per share	$	(0.60	)	$	(0.41	)	$	(0.38	)	$	(0.45	)
Shares used to compute basic and diluted net loss per share		41,830			49,700			57,650			61,007

Organization - Additional Information (Detail)	12 Months Ended
Organization - Additional Information (Detail)	Dec. 31, 2018
HEPLISAV-B
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Minimum age approved for vaccine prevention of infection caused	18 years

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($) Segment	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of operating segment \| Segment	1
Cash, cash equivalents and marketable securities	$ 145,500,000
Impairment of Intangible assets	0	$ 0	$ 0
Impairments of tangible assets	0	0	0
Goodwill impairments	$ 0	$ 0	$ 0
Federal corporate income tax rate	21.00%
Cost of Sales - Product
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Inventory reserves	$ 1,000,000
Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, customer	three largest customers
Trade Receivable \| Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, percentage	71.00%
Product \| Revenue \| Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, percentage	68.00%
United States
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of revenue earned	83.00%	90.00%	92.00%
Percentage of long lived assets	24.00%	15.00%
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cash equivalents original maturity period	3 months
Expected period of payment to be received	1 year
Maximum \| Subsequent Event
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Right-of-use asset for operating leases				$ 40,000,000
Lease Liabilities for operating leases				40,000,000
Minimum \| Subsequent Event
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Right-of-use asset for operating leases				34,000,000
Lease Liabilities for operating leases				$ 34,000,000
Dynavax GmbH
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Currency translation adjustments	$ (1,100,000)	$ 2,800,000	$ (700,000)
Currency transaction gain (loss)	$ 300,000	$ (600,000)	$ 200,000

Fair Value Measurements - Additional Information (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers from level 1 to level 2	$ 0	$ 0
Transfers from level 2 to level 1	0	0
Other current liabilities	7,000,000
Other long-term liabilities	8,915,000	$ 643,000
Merck, Sharp & Dohme Corp.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other current liabilities	7,000,000
Merck, Sharp & Dohme Corp. \| Fair Value, Inputs, Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other long-term liabilities	$ 6,300,000

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 142,389	$ 187,813
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	44,002	22,543
U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	14,724	45,534
U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	42,372	86,820
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	41,291	32,916
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	44,002	22,543
Fair Value, Inputs, Level 1 \| Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	44,002	22,543
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	98,387	165,270
Fair Value, Inputs, Level 2 \| U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	14,724	45,534
Fair Value, Inputs, Level 2 \| U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	42,372	86,820
Fair Value, Inputs, Level 2 \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 41,291	$ 32,916

Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 49,348	$ 26,584	$ 24,289
Restricted cash	619	629	602
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 49,967	$ 27,213	$ 24,891	$ 45,421

Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	$ 145,604	$ 191,934
Unrealized Losses	(68)	(80)
Estimated Fair Value	145,536	191,854
Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	49,348	26,584
Estimated Fair Value	49,348	26,584
Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	96,256	165,350
Unrealized Losses	(68)	(80)
Estimated Fair Value	96,188	165,270
Cash \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	3,147	4,041
Estimated Fair Value	3,147	4,041
Money Market Funds \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	44,002	22,543
Estimated Fair Value	44,002	22,543
Corporate Debt Securities \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	2,199
Estimated Fair Value	2,199
Corporate Debt Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	39,108	32,931
Unrealized Losses	(16)	(15)
Estimated Fair Value	39,092	32,916
U.S. Treasuries \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	14,732	45,559
Unrealized Losses	(8)	(25)
Estimated Fair Value	14,724	45,534
U.S. Government Agency Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	42,416	86,860
Unrealized Losses	(44)	(40)
Estimated Fair Value	$ 42,372	$ 86,820

Maturities of Marketable Securities Available-for-Sale (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Amortized Cost
Mature in one year or less	$ 96,256
Mature after one year through two years	0
Total amortized cost	96,256
Estimated Fair Value
Mature in one year or less	96,188
Mature after one year through two years	0
Total estimated fair value	$ 96,188

Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Investments Debt And Equity Securities [Abstract]
Realized gains or losses from the sale of marketable securities	$ 0	$ 0	$ 0

Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 12,111
Work-in-process	6,562	$ 312
Finished goods	349
Total	$ 19,022	$ 312

Intangible Assets, Net - Summary of Intangible Assets, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite Lived Intangible Assets Net [Abstract]
Intangible assets	$ 19,773	$ 2,500
Less accumulated amortization	(8,056)	(1,194)
Total	$ 11,717	$ 1,306

Intangible Assets, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]
Cost of sales - amortization of intangible assets	$ 10,862,000	$ 1,194,000
Estimated remaining useful life of intangible assets	16 months
Impairment of intangible assets	$ 0
Merck
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	8,100,000
GlaxoSmithKline Biologicals SA
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	1,500,000
Coley Pharmaceutical Group, Inc.
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 1,300,000

Component of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Manufacturing equipment	$ 12,029	$ 12,104
Lab equipment	6,938	6,686
Computer equipment	5,465	4,760
Furniture and fixtures	1,809	1,629
Leasehold improvements	11,367	10,873
Assets in progress	2,605	1,176
Property, Plant and Equipment, Gross	40,213	37,228
Less accumulated depreciation and amortization	(23,149)	(20,609)
Total	$ 17,064	$ 16,619
Manufacturing Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Manufacturing Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	14 years
Lab Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Lab Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	13 years
Computer Equipment
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Furniture and Fixtures \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Furniture and Fixtures \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	13 years
Leasehold Improvements \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	1 year
Leasehold Improvements \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation and amortization	$ 3,621	$ 3,244	$ 2,257

Component of Current Accrued Liabilities and Accrued Research and Development (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities Abstract
Payroll and related expenses	$ 8,058	$ 6,180
Legal expenses	151	346
Revenue reserves liability	1,033
Third party research expenses	7,819	3,567
Third party development expenses	1,377	522
Other accrued liabilities	7,317	3,439
Total	$ 25,755	$ 14,054

Commitments and Contingencies - Additional Information (Detail) € in Millions				1 Months Ended				12 Months Ended
	Sep. 17, 2018 USD ($) ft²	Oct. 24, 2017 USD ($)	Sep. 07, 2016 USD ($)	Feb. 29, 2020 USD ($)	Feb. 28, 2019 USD ($)	Feb. 28, 2018 USD ($)	Nov. 30, 2009 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2004 USD ($)	Dec. 31, 2018 EUR (€)	Dec. 31, 2017 EUR (€)	Dec. 31, 2004 EUR (€)
Loss Contingencies [Line Items]
Rent expense								$ 4,000,000	$ 2,400,000	$ 2,200,000
Deferred rent								2,300,000	600,000
Maximum borrowing capacity						$ 175,000,000
Principal amount including interest paid in kind						$ 101,800,000
Debt maturity date						Dec. 31, 2023
Cash, cash equivalents and marketable securities								$ 145,500,000
Litigation settlement agreement date								September 7, 2016
Litigation amount payable		$ 900,000
Dynavax Technologies Securities Litigation
Loss Contingencies [Line Items]
Litigation amount payable			$ 4,100,000
Symphony Dynamo Holdings LLC
Loss Contingencies [Line Items]
License arrangement contingent consideration percentage							50.00%
License arrangement upfront payment							$ 50,000,000
Milestone payments								$ 0	0
Deutsche Bank Securities
Loss Contingencies [Line Items]
Letter of credit pledged as security \| €														€ 0.2
Collateralized certificate of deposit \| €												€ 0.2	€ 0.2
Sublicense Agreement \| Merck
Loss Contingencies [Line Items]
Payment upon obligation						$ 7,000,000
Scenario, Forecast \| Sublicense Agreement \| Merck
Loss Contingencies [Line Items]
Payment upon obligation				$ 7,000,000	$ 7,000,000
Emeryville, California (Premises)
Loss Contingencies [Line Items]
Letter of credit pledged as security											$ 400,000
Collateralized certificate of deposit								$ 400,000	$ 400,000
Terms of the lease								If the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.
Emeryville, California (Premises) \| Contingency, B
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities											12 months
Emeryville, California (Premises) \| Contingency, A
Loss Contingencies [Line Items]
Increase in amount of the security deposit											$ 1,100,000
Emeryville, California (Premises) \| Maximum \| Contingency, A
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities											20,000,000
Emeryville, California (Premises) \| Minimum \| Contingency, B
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities											$ 20,000,000
Emeryville, California (Premises) \| Minimum \| Contingency, A
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities											30 days
Office and Laboratory Space \| Emeryville, California (Premises)
Loss Contingencies [Line Items]
Lease area \| ft²	75,662
Base rent per square feet	$ 4.75
Operations commencement date	Apr. 01, 2019
Initial lease term	12 years
Lease option to extend	The Lease has an initial term of 12 years, following the Commencement Date with an option to extend the lease for two successive five-year terms
Renewal term of lease	5 years
Office and Laboratory Space \| Emeryville, California (Premises) \| Maximum
Loss Contingencies [Line Items]
Tenant improvement allowance	$ 8,300,000

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases and Non-Cancelable Purchase Commitments (Detail) - Term Loan and Sublicense Agreement $ in Thousands	Dec. 31, 2018 USD ($)
Future Minimum Payments Under Noncancelable Operating Leases And Purchase Commitments [Line Items]
2019	$ 22,378
2020	12,256
2021	5,144
2022	5,212
2023	109,760
Thereafter	39,523
Total	$ 194,273

Collaborative Research, Development and License Agreements - Additional Information (Detail) $ in Thousands		1 Months Ended			3 Months Ended										8 Months Ended	12 Months Ended
	Jul. 12, 2018 USD ($)	Feb. 28, 2018 USD ($) Installment	Jan. 31, 2018 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jul. 31, 2018	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized							$ 5,318	$ 1,461	$ 1,254	$ 165	$ 21	$ 53	$ 105	$ 148		$ 8,198	$ 327	$ 11,043
Intangible assets, net							11,717									11,717
Collaboration Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized																1,386		$ 9,778
Astra Zeneca \| Collaboration Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized				$ 9,800
Merck, Sharp & Dohme Corp. \| Sublicense Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate amount payable to acquire intangible assets		$ 21,000
Number of installments \| Installment		3
Payment upon obligation		$ 7,000
Intangible assets		$ 19,800
Intangible assets, net							$ 11,700									11,700
Merck, Sharp & Dohme Corp. \| Sublicense Agreement \| Scenario, Forecast
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment upon obligation					$ 7,000	$ 7,000
GlaxoSmithKline Biologicals SA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of royalty on net sales															13.00%
GlaxoSmithKline Biologicals SA \| License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment upon obligation	$ 1,500
GlaxoSmithKline Biologicals SA \| Royalty
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties in cost of sales																$ 200
Coley Pharmaceutical Group, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination date																2018-02
Amortization of intangible assets																$ 2,500
Coley Pharmaceutical Group, Inc. \| Intangible Assets
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment upon obligation			$ 2,500

Long-Term Debt - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Feb. 20, 2018	Feb. 28, 2018	Dec. 31, 2016	Dec. 31, 2018	Oct. 31, 2016
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 175,000
Net proceeds from the initial term loan				$ 99,000
Principal amount including interest paid in kind		$ 101,800
Debt maturity date		Dec. 31, 2023
Note Purchase Agreement
Debt Instrument [Line Items]
Aggregate purchase price					$ 100,000
Amount paid to lender upon entering into agreement					1,000
Amount incurred in securing agreement					$ 1,600
Debt instrument, termination fee			$ 1,500
Loan Agreement
Debt Instrument [Line Items]
Percentage of capital stock of subsidiaries subject to certain exception	65.00%
Debt instrument, covenant daily minimum combined cash and investment balance	$ 15,000
Interest expense related to initial term loan				$ 8,800
Loan Agreement \| Maximum
Debt Instrument [Line Items]
Percentage of repayment premium of principal amount prepaid	7.00%
CRG Servicing LLC
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 175,000
Current borrowing capacity	100,000
Additional borrowing capacity	75,000
Net proceeds from the initial term loan	$ 99,000
Debt interest rate	9.50%
Debt instrument interest rate, effective percentage				10.10%
Principal amount including interest paid in kind				$ 101,800
Debt maturity date	Dec. 31, 2023

Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail) - HEPLISAV-B® $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Product Revenue Allowance and Revenue Categories [Line Items]
Provision related to current period sales	$ 4,582
Credit or payments made during the period	(2,277)
Balance at December 31, 2018	2,305
Chargebacks, Discounts and Other Fees
Product Revenue Allowance and Revenue Categories [Line Items]
Provision related to current period sales	4,012
Credit or payments made during the period	(2,276)
Balance at December 31, 2018	1,736
Returns
Product Revenue Allowance and Revenue Categories [Line Items]
Provision related to current period sales	570
Credit or payments made during the period	(1)
Balance at December 31, 2018	$ 569

Revenue Recognition - Additional Information (Detail) $ in Millions	Dec. 31, 2018 USD ($)
Product Revenue Allowance and Revenue Categories [Line Items]
Remaining reserves balances recorded as accrued liabilities	$ 1.0
Chargebacks and Discounts
Product Revenue Allowance and Revenue Categories [Line Items]
Reserves recorded as reduction of accounts receivable	$ 1.3

Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Basic and diluted net loss per share (in thousands, except per share amounts):
Net loss	$ (39,969)	$ (40,528)	$ (39,444)	$ (38,958)	$ (27,421)	$ (22,128)	$ (20,318)	$ (25,287)	$ (158,899)	$ (95,154)	$ (112,444)
Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding	62,694	62,650	62,346	61,744	61,007	57,650	49,700	41,830	62,362	52,613	38,506
Basic and diluted net loss per share	$ (0.64)	$ (0.65)	$ (0.63)	$ (0.63)	$ (0.45)	$ (0.38)	$ (0.41)	$ (0.60)	$ (2.55)	$ (1.81)	$ (2.92)
Stock Options and Stock Awards
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									7,344	5,981	4,673

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Common Stock - Additional Information (Detail) - USD ($)		1 Months Ended	2 Months Ended	12 Months Ended
	Nov. 03, 2017	Aug. 31, 2017	Feb. 22, 2019	Dec. 31, 2018	Dec. 31, 2017
Class Of Stock [Line Items]
Common stock, shares outstanding				62,862,478	61,533,000
Net cash proceeds received					$ 185,936,000
Common Stock
Class Of Stock [Line Items]
Issuance of common stock (in shares)					22,588,000
2017 ATM Agreement
Class Of Stock [Line Items]
Issuance of common stock (in shares)					840,774
Net cash proceeds received					$ 16,900,000
Remaining proceeds from common stock, under sales agreement				$ 132,800,000
2017 ATM Agreement \| Subsequent Event
Class Of Stock [Line Items]
Issuance of common stock (in shares)			1,078,901
Net cash proceeds received			$ 11,500,000
Underwritten Public Offering \| Common Stock
Class Of Stock [Line Items]
Issuance of common stock (in shares)		5,750,000
Public offering net price per share		$ 15.00
Net proceeds from offering		$ 80,800,000
Over-Allotment Option \| Common Stock
Class Of Stock [Line Items]
Issuance of common stock (in shares)		750,000
2015 ATM Agreement
Class Of Stock [Line Items]
Issuance of common stock (in shares)					15,997,202
Net cash proceeds received					$ 88,200,000
Maximum \| 2017 ATM Agreement
Class Of Stock [Line Items]
Common stock sales agreement aggregate sales proceeds	$ 150,000,000
Commission on gross sales proceeds of common stock	3.00%

Equity Plans and Stock-Based Compensation - Additional Information (Detail) - USD ($)			12 Months Ended
	May 31, 2018	May 28, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding stock awards granted			5,750,000	3,555,000
Total intrinsic value of options exercised			$ 200,000	$ 900,000	$ 200,000
Total fair value of stock options vested			8,100,000	13,000,000	12,100,000
Stock-based compensation expense			$ 23,478,000	14,917,000	14,126,000
Expected dividend yield			0.00%
Cash-settled portion of stock compensation expense			$ 0	$ 0	$ 602,000
Increase in aggregate number of shares of common stock authorized for issuance	600,000
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense related to restricted stock			8,400,000
Aggregate intrinsic value			$ 14,600,000
Grant date fair value of restricted stock			$ 15.98	$ 5.34	$ 12.42
Total fair value of restricted stock units			$ 19,400,000	$ 1,200,000	$ 1,000,000
Restricted stock unit awards outstanding			1,594,000	2,443,000
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding stock awards granted			151,000
Performance Based Vesting Condition Not Probable
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock unit awards outstanding			5,000
Performance Based Vesting Condition
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock unit awards outstanding			12,500,000
Stock-based compensation expense			$ 1,900,000	$ 300,000	$ 500,000
Maximum \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period			10 years
Options vesting period			3 years
Minimum \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period			7 years
Options vesting period			4 years
2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Newly reserved shares of common stock	5,000,000
Shares remaining available for future purchases	140,250
Outstanding stock awards granted	7,477,619		5,750,404
Expiration period	7 years
Shares reserved and approved for issuance			4,810,112
2018 Equity Incentive Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock shares	12,617,869
Time Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards			$ 26,100,000
Total unrecognized compensation cost, weighted-average vesting period			1 year 10 months 24 days
Performance Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards			$ 300,000
2014 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards			$ 500,000
Total unrecognized compensation cost, weighted-average vesting period			1 year 7 months 6 days
Shares issued to employees			125,193
Shares remaining available for future purchases			573,034
2014 Employee Stock Purchase Plan \| The commencement of the offer period (generally, the sixteenth day in February or August)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock		85.00%
2014 Employee Stock Purchase Plan \| The exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock		85.00%

Option Activity under Stock-Based Compensation Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares
Shares Underlying Outstanding Options
Beginning balance \| shares	3,555
Options granted \| shares	2,503
Options exercised \| shares	(42)
Ending balance \| shares	5,750
Vested and expected to vest at December 31, 2018 \| shares	5,534
Exercisable at December 31, 2018 \| shares	2,975
Weighted-Average Exercise Price Per Share
Beginning balance \| $ / shares	$ 19.56
Options granted \| $ / shares	16.30
Options exercised \| $ / shares	11.80
Ending balance \| $ / shares	18.20
Vested and expected to vest at December 31, 2018 \| $ / shares	18.28
Exercisable at December 31, 2018 \| $ / shares	$ 19.90
Weighted-Average Remaining Contractual Term (years)
Balance at December 31, 2018	5 years 5 months 19 days
Vested and expected to vest at December 31, 2018	5 years 5 months 8 days
Exercisable at December 31, 2018	4 years 10 months 13 days
Aggregate Intrinsic Value
Balance at December 31, 2018 \| $	$ 651
Vested and expected to vest at December 31, 2018 \| $	644
Exercisable at December 31, 2018 \| $	$ 466
Unvested
Shares Underlying Outstanding Options
Options cancelled \| shares	(178)
Weighted-Average Exercise Price Per Share
Options cancelled \| $ / shares	$ 14.29
Vested
Shares Underlying Outstanding Options
Options cancelled \| shares	(88)
Weighted-Average Exercise Price Per Share
Options cancelled \| $ / shares	$ 29.58

Summary of Non-vested Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Non-vested, Beginning Balance	2,443
Granted	458
Vested	(1,219)
Forfeited	(88)
Non-vested, Ending Balance	1,594	2,443
Weighted-Average Grant-Date Fair Value
Non-vested, Beginning Balance	$ 6.01
Granted	15.98	$ 5.34	$ 12.42
Vested	5.86
Forfeited	9.07
Non-vested, Ending Balance	$ 8.82	$ 6.01

Fair Value-Based Measurements and Weighted-Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value	$ 8.30	$ 3.05	$ 7.86
Risk-free interest rate	2.40%	1.00%	0.60%
Expected life (in years)	1 year 3 months 18 days	1 year 2 months 12 days	1 year 2 months 12 days
Expected Volatility	1.10%	1.00%	0.60%
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value	$ 10.75	$ 8.27	$ 9.54
Risk-free interest rate	2.50%	1.90%	1.40%
Expected life (in years)	4 years 2 months 12 days	4 years 6 months	4 years 10 months 24 days
Expected Volatility	0.80%	0.90%	0.70%

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 23,478	$ 14,917	$ 14,126
Inventory
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	759
Employees And Directors
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	23,478	14,917	14,126
Research and Development
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	9,604	7,827	6,742
Selling, General and Administrative
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	11,761	$ 7,090	$ 7,384
Cost of Sales - Product
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 1,354

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Pension And Other Postretirement Benefit Expense [Abstract]
Contributions to 401 (k) plan	$ 0.2	$ 0.2	$ 0.2

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Dec. 31, 2017
Restructuring Cost And Reserve [Line Items]
Percentage of reduction in global workforce	40.00%
Restructuring			$ 2,783
Employee Severance and Other Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring		$ 2,800
Cash payments			$ 2,800

Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S.	$ (160,032)	$ (95,898)	$ (114,484)
Non U.S.	1,133	744	2,040
Total	$ (158,899)	$ (95,154)	$ (112,444)

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Line Items]
Income tax expense	$ 0	$ 0	$ 0
Increase (decrease) in valuation allowance	$ 40,400,000	(108,800,000)
Federal corporate income tax rate	21.00%
Unrecognized tax benefits	$ 1,229,000	$ 1,229,000
Unrecognized tax benefits would affect the effective tax rate	0
Interest related to unrecognized tax benefits	0
Penalties related to unrecognized tax benefits	0
Federal
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 771,800,000
Federal \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2019
Federal \| Research And Development Tax Credits
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 19,900,000
Federal \| Research And Development Tax Credits \| Minimum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2019
Federal \| Research And Development Tax Credits \| Maximum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2038
California and Other States
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 229,000,000
California and Other States \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2019
California and Other States \| Maximum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2038
California State \| Research And Development Tax Credits
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 19,100,000
Foreign
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 11,900,000

Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	$ (33,366,000)	$ (32,352,000)	$ (38,183,000)
State tax	(5,591,000)	(4,482,000)	(334,000)
Business credits	(3,065,000)	(1,960,000)	(1,950,000)
Deferred compensation charges	(1,165,000)	3,823,000	3,016,000
Change in valuation allowance	43,134,000	(109,165,000)	36,751,000
Rate change		86,943,000
Net operating loss and tax credit limitation		56,962,000
Other	53,000	231,000	700,000
Total income tax expense	$ 0	$ 0	$ 0

Component of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carry forwards	$ 178,730	$ 146,300
Research tax credit carry forwards	34,064	29,658
Accruals and reserves	10,137	6,551
Capitalized research costs	943	1,422
Other	1,147	731
Total deferred tax assets	225,021	184,662
Less valuation allowance	(224,746)	(184,388)
Net deferred tax assets	275	274
Deferred tax liabilities:
Fixed assets	(275)	(274)
Total deferred tax liabilities	$ (275)	$ (274)

Schedule of Unrecognized Tax Benefits (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Income Tax Disclosure [Abstract]
Balance at December 31, 2017	$ (1,229)
Balance at December 31, 2018	$ (1,229)

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 5,318	$ 1,461	$ 1,254	$ 165	$ 21	$ 53	$ 105	$ 148	$ 8,198	$ 327	$ 11,043
Net loss	$ (39,969)	$ (40,528)	$ (39,444)	$ (38,958)	$ (27,421)	$ (22,128)	$ (20,318)	$ (25,287)	$ (158,899)	$ (95,154)	$ (112,444)
Basic and diluted net loss per share	$ (0.64)	$ (0.65)	$ (0.63)	$ (0.63)	$ (0.45)	$ (0.38)	$ (0.41)	$ (0.60)	$ (2.55)	$ (1.81)	$ (2.92)
Shares used to compute basic and diluted net loss per share	62,694	62,650	62,346	61,744	61,007	57,650	49,700	41,830	62,362	52,613	38,506

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details